Posted by Michael Wonder on 30 Aug 2021
FDA orphan drug approval: Octapharma’s Octagam 10% receives 7 years of market exclusivity for adult dermatomyositis
30 August 2021 - Octagam 10% expected to become the first treatment option for adults with rare immune-mediated inflammatory disease.
Octapharma USA today announced the U.S. FDA Office of Orphan Products Development has awarded seven years of marketing exclusivity for Octagam 10% [immune globulin intravenous (human)], the first and only intravenous immunoglobulin to be indicated for the treatment of adult dermatomyositis.
